Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials

Author(s): Costa J, Borges M, David C, Vaz Carneiro A

Abstract

Objective: To evaluate the clinical benefit of lipid lowering drug treatment in patients with and without diabetes mellitus, for primary and secondary prevention.

Design: Systematic review and meta-analysis.

Data sources: Cochrane, Medline, Embase, and reference lists up to April 2004.

Study selection: Randomised, placebo controlled, double blind trials with a follow-up of at least three years that evaluated lipid lowering drug treatment in patients with and without diabetes mellitus.

Data extraction: Two independent reviewers extracted data. The primary outcome was major coronary events defined as coronary heart disease death, non-fatal myocardial infarction, or myocardial revascularisation procedures.

Results: Twelve studies were included. Lipid lowering drug treatment was found to be at least as effective in diabetic patients as in non-diabetic patients. In primary prevention, the risk reduction for major coronary events was 21% (95% confidence interval 11% to 30%; P < 0.0001) in diabetic patients and 23% (12% to 33%; P = 0.0003) in non-diabetic patients. In secondary prevention, the corresponding risk reductions were 21% (10% to 31%; P = 0.0005) and 23% (19% to 26%; P < or = 0.00001). However, the absolute risk difference was three times higher in secondary prevention. When results were adjusted for baseline risk, diabetic patients benefited more in both primary and secondary prevention. Blood lipids were reduced to a similar degree in both groups.

Conclusions: The evidence that lipid lowering drug treatment (especially statins) significantly reduce cardiovascular risk in diabetic and non-diabetic patients is strong and suggests that diabetic patients benefit more, in both primary and secondary prevention. Future research should define the threshold for treatment of these patients and the desired target lipid concentrations, especially for primary prevention.

Similar Articles

Global guidelines for type 2 diabetes

Author(s): IDF Clinical Guidelines Task Force

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

Author(s): Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, et al.

Computer modeling of diabetes and its complications

Author(s): The Mount Hood 4 Modeling Group

A clinical prediction rule for delirium after elective noncardiac surgery

Author(s): Marcantonio ER, Goldman L, Mangione CM, Ludwig LE, Muraca B, et al.

Blood pressure, lipids, and obesity are associated with retinopathy: the hoorn study

Author(s): van Leiden HA, Dekker JM, Moll AC, Nijpels G, Heine RJ, et al.

The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)

Author(s): Stevens RJ, Kothari V, Adler AI, Stratton IM; United Kingdom Prospective Diabetes Study (UKPDS) Group

Risk factors for diabetic peripheral sensory neuropathy

Author(s): Adler AI, Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, et al.

Risk factors for renal dysfunction in type 2 diabetes: U

Author(s): Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR

Preserving renal function in adults with hypertension and diabetes: a consensus approach

Author(s): Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, et al.

Incidence and determinants of microalbuminuria in Koreans with type 2 diabetes

Author(s): Park JY, Kim HK, Chung YE, Kim SW, Hong SK, et al.

Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension

Author(s): Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, et al.

The Metabolic Syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects

Author(s): Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, et al.